when were glp 1 agonists approved History of glucagon-like peptide-1 receptor How Can GLP-1 Agonists Be

Data are presented as medians (interquartile ranges) or frequencies (%), and Wilcoxon signed-rank tests and Mann-Whitney U tests were used for paired and nonpaired group comparisons, respectively

Why? Fatigue is a frequent complaint for those on GLP-1 medications

The year delivered progress across clinical evidence, policy, and changing market dimensions, reinforcing obesity as a chronic disease requiring structured, long-term management

The global incretin-based drugs market was valued at USD 39.4 billion in 2025 and is projected to grow from USD 41.6 billion in 2026 to USD 72.6 billion by 2035, expanding at a CAGR of 6.4% between 2026 and 2035, driven by the rising prevalence of type 2 diabetes mellitus.

What matters most though is what patients are experiencing are they able to reliably access their medication

Grading of Recommendations Assessment, Development and Evaluation (GRADE) showed moderate certainty for MACE, all-cause death and hospitalization for HF